• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

盐酸考来烯胺促进特立氟胺消除的耐受性和疗效。

Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.

作者信息

Robertson Derrick, Dixon Crystal, Aungst Angela, McCoy Bradlee, Moreo Natalie, Casady Lise, Maldonado Janice

机构信息

a Department of Neurology , University of South Florida, College of Medicine , Tampa , FL , USA.

出版信息

Expert Rev Clin Pharmacol. 2017 Dec;10(12):1403-1407. doi: 10.1080/17512433.2017.1395280. Epub 2017 Nov 2.

DOI:10.1080/17512433.2017.1395280
PMID:29064296
Abstract

BACKGROUND

Teriflunomide is an oral disease modifying therapy approved for the treatment of relapsing forms of multiple sclerosis. Teriflunomide' s pharmacokinetics (PK) contribute to its slow elimination, on average taking 6-8 months, though it can take up to 2 years in some instances. This slow elimination can become problematic in certain clinical situations - such as during pregnancy, when teriflunomide has potential teratogenic effects. In such scenarios, an accelerated elimination procedure (AEP) is recommended. Currently, AEPs with oral cholestyramine or activated charcoal are available but are restricted by adverse effects, limited administration routes, and dosing frequencies.

METHODS

A single-center, PK interaction study was performed in a total of 14 healthy volunteers, to investigate colestipol hydrochloride (HCl) as an alternative to cholestyramine for the elimination of teriflunomide. Participants received teriflunomide for 14 days, followed by an AEP with colestipol HCl for 15 days.

RESULTS AND CONCLUSIONS

The administration of colestipol HCl for 15 days was sufficient to reduce plasma teriflunomide concentrations by greater than 96%. Although colestipol HCl did not completely eliminate teriflunomide with the same effectiveness as cholestyramine, it may offer an alternative method for accelerated elimination of teriflunomide with potentially improved tolerability and more favorable dosing and administration options.

摘要

背景

特立氟胺是一种口服疾病修正疗法,已被批准用于治疗复发型多发性硬化症。特立氟胺的药代动力学(PK)导致其消除缓慢,平均需要6 - 8个月,尽管在某些情况下可能需要长达2年。这种缓慢消除在某些临床情况下可能会成为问题,例如在怀孕期间,此时特立氟胺具有潜在的致畸作用。在这种情况下,建议采用加速消除程序(AEP)。目前,口服考来烯胺或活性炭的AEP可用,但受到不良反应、给药途径有限和给药频率的限制。

方法

在总共14名健康志愿者中进行了一项单中心PK相互作用研究,以研究盐酸考来替泊作为考来烯胺替代物用于消除特立氟胺的效果。参与者接受特立氟胺治疗14天,随后接受盐酸考来替泊的AEP治疗15天。

结果与结论

给予盐酸考来替泊15天足以使血浆特立氟胺浓度降低超过96%。虽然盐酸考来替泊不能像考来烯胺那样完全有效地消除特立氟胺,但它可能为加速消除特立氟胺提供一种替代方法,具有潜在改善的耐受性以及更有利的给药和用药选择。

相似文献

1
Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.盐酸考来烯胺促进特立氟胺消除的耐受性和疗效。
Expert Rev Clin Pharmacol. 2017 Dec;10(12):1403-1407. doi: 10.1080/17512433.2017.1395280. Epub 2017 Nov 2.
2
Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.多发性硬化症患者停用特立氟胺后的反弹:2 例报告。
Mult Scler Relat Disord. 2020 Jun;41:102017. doi: 10.1016/j.msard.2020.102017. Epub 2020 Feb 24.
3
Effectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Participants.盐酸考来维仑加速健康受试者体内特立氟胺消除的有效性和耐受性
J Clin Pharmacol. 2017 Jun;57(6):747-750. doi: 10.1002/jcph.854. Epub 2017 Jan 25.
4
Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide.树脂和活性炭对地高辛、卡马西平和呋塞米吸收的影响。
Br J Clin Pharmacol. 1988 Feb;25(2):229-33. doi: 10.1111/j.1365-2125.1988.tb03295.x.
5
The effect of colestipol and cholestyramine on the systemic clearance of intravenous ibuprofen in rabbits.考来替泊和考来烯胺对兔静脉注射布洛芬全身清除率的影响。
J Pharm Pharmacol. 1994 Jan;46(1):73-5. doi: 10.1111/j.2042-7158.1994.tb03724.x.
6
Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.特立氟胺:一种用于治疗复发型多发性硬化症的每日一次口服药物。
Clin Ther. 2015 Oct 1;37(10):2366-80. doi: 10.1016/j.clinthera.2015.08.003. Epub 2015 Sep 11.
7
The effect of colestipol and cholestyramine on ibuprofen bioavailability in man.
Biopharm Drug Dispos. 1994 Aug;15(6):463-71. doi: 10.1002/bdd.2510150604.
8
Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.特立氟胺:一种用于复发型多发性硬化症的新型口服治疗药物。
Expert Opin Pharmacother. 2014 May;15(7):1019-27. doi: 10.1517/14656566.2014.902936. Epub 2014 Apr 17.
9
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.来氟米特治疗多发性硬化症的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1025-35. doi: 10.1517/17425255.2013.800483. Epub 2013 May 17.
10
The effects of cholestyramine and colestipol on the absorption of diclofenac in man.
Int J Clin Pharmacol Ther. 1994 Aug;32(8):441-5.

引用本文的文献

1
Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review.药物性肝损伤治疗的新型疗法:一项系统评价
Front Pharmacol. 2022 Feb 2;12:785790. doi: 10.3389/fphar.2021.785790. eCollection 2021.
2
Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children.针对希望生育的多发性硬化症患者的实用循证建议。
Neurol Ther. 2018 Dec;7(2):207-232. doi: 10.1007/s40120-018-0110-3. Epub 2018 Aug 30.